Journal Logo

Articles by M. Fanale

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS: PS1070

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3:484-485, June 2019.